Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unfractionated heparin versus fondaparinux in severe sepsis
ACTRN12607000157471Phase 2Terminated
- Sponsor
- Dr Megan S Robertson
- Start
- Nov 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sepsis comparing Unfractionated heparin control with Fondaparinux intervention (2 arms). Primary endpoints: Survival from severe sepsis and All-cause mortality. Started Nov 2007; status: terminated.
02
Drugs
heparinfondaparinux
03
Conditions
sepsis
Beyond the preview
Go deeper on ACTRN12607000157471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000157471.